title: Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
abstract: A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
authors.affiliation: Boston University School of Law, Boston, Massachusetts 02215, USA.|Chatham House, London SW1Y 4LE, UK.
authors.forename: Kevin
authors.initials: K
authors.lastname: Outterson
authors.affiliation: AstraZeneca Pharmaceuticals, Waltham, Massachusetts 02451, USA.|University of Texas Medical School-Houston, Houston, Texas 77225, USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Rex
authors.affiliation: Wellcome Trust, London NW1 2BE, UK.
authors.forename: Tim
authors.initials: T
authors.lastname: Jinks
authors.affiliation: AMR Centre, Alderley Park, Manchester SK10 4TG, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Jackson
authors.affiliation: Mass Bio, Cambridge, Massachusetts 02139, USA.
authors.forename: John
authors.initials: J
authors.lastname: Hallinan
authors.affiliation: California Life Sciences Institute, South San Francisco, California 94080, USA.
authors.forename: Steve
authors.initials: S
authors.lastname: Karp
authors.affiliation: Broad Institute, Cambridge, Massachusetts 02142, USA.|Harvard Medical School, Boston, Massachusetts 02215, USA.|Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
authors.forename: Deborah T
authors.initials: DT
authors.lastname: Hung
authors.affiliation: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
authors.forename: Francois
authors.initials: F
authors.lastname: Franceschi
authors.affiliation: Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
authors.forename: Tyler
authors.initials: T
authors.lastname: Merkeley
authors.affiliation: Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Houchens
authors.affiliation: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Dixon
authors.affiliation: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Kurilla
authors.affiliation: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
authors.forename: Rosemarie
authors.initials: R
authors.lastname: Aurigemma
authors.affiliation: Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Larsen
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D035843:Biomedical Research / Q000191:economics / Q000458:organization & administration; D002986:Clinical Trials as Topic; D024881:Drug Resistance, Bacterial; D006801:Humans; D055818:Public-Private Sector Partnerships
chemical_list: D000900:Anti-Bacterial Agents